1
Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera: Anti-HCV nucleoside derivatives. Hoffmann la Roche, George W Johnston, Dennis P Tramaloni, Lyman H Smith, December 9, 2003: US06660721 (81 worldwide citation)

The present invention comprises nucleoside derivatives for use in the treatment or prophylaxis of hepatitis C virus infections. In particular, the present invention discloses the novel use of known 2′-deoxy-2′-fluoro nucleoside derivatives as inhibitors of hepatitis C virus (HCV) RNA replication and ...


2
Rene Devos, Brian William Dymock, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda: Anti-HCV nucleoside derivatives. Hoffmann La Roche, Patent Law Department, June 10, 2004: US20040110718-A1

The present invention comprises novel and known purine and pyrimidine nucleoside derivatives which have been discovered to be active against hepatitis C virus (HCV). The use of these derivatives for the treatment of HCV infection is claimed as are the novel nucleoside derivatives disclosed herein.


3
Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera: Anti-HCV nucleoside derivatives. Hoffmann La Roche, Patent Law Department, May 1, 2003: US20030083307-A1

The present invention comprises nucleoside derivatives for use in the treatment or prophylaxis of hepatitis C virus infections. In particular, the present invention discloses the novel use of known 2-deoxy-2-fluoro nucleoside derivatives as inhibitors of hepatitis C virus (HCV) RNA replication and p ...


4
Rene Devos, Brian William Dymock, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda: Anti-HCV nucleoside derivatives. Hoffmann La Roche, Patent Law Department, January 9, 2003: US20030008841-A1

The present invention comprises novel and known purine and pyrimidine nucleoside derivatives which have been discovered to be active against hepatitis C virus (HCV). The use of these derivatives for the treatment of HCV infection is claimed as are the novel nucleoside derivatives disclosed herein.